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Cost-effectiveness analysis (CEA) represents the most
important tool in the health economics literature to quan-
tify and qualify the reasoning behind the optimal decision
process in terms of the allocation of resources to a given
health intervention. However, the practical application of
CEA in regulatory process is often limited by some critical
barriers, and decisions in clinical practice are frequently
influenced by factors that do not contribute to an efficient
resources allocation, leading to inappropriate drug pre-
scription and utilisation. Moreover, most of the times
there is uncertainty about the real cost-effectiveness profile
of an innovative intervention, with the consequence that it
is usually impossible to obtain an immediate and perfect
substitution of an intervention with another having a
better cost-effectiveness ratio. We propose a rational
approach to CEA within regulatory processes basing our
analysis in a Bayesian decision-theoretic framework and
proposing an extension of the application of well known
tools (such as the expected value of information) to such
cases. The regulator can use these tools to identify the
economic value of reducing the uncertainty surrounding
the cost-effectiveness profile of the several alternatives.
This value can be compared to the one that is generated
by the actual combination (in terms of market shares) of
different options: one that is the most cost-effective and
others in the same therapeutic category that, despite pro-
ducing clinical benefits, are less cost-effective. We use pre-
scription of statins as a case study.
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